Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences, Inc. executive Keeley M Cain Wettan, EVP Gen Counsel, Legal & Comp, reported a derivative exercise on restricted stock units. On 2026-08-10, 6,002 restricted stock units converted into 6,002 shares of common stock, and 2,908 common shares at $133.06 per share were delivered or withheld for payment of exercise price or tax liability. Following the transaction, the reporting person held 13,995 restricted stock units directly.
Gilead Sciences, Inc. has filed an automatic shelf registration statement on Form S-3, allowing it to offer from time to time a broad range of securities, including senior debt, common stock, preferred stock, depositary shares, warrants, subscription rights, stock purchase contracts and stock purchase units. Specific amounts, prices and terms for each issuance will be set in future prospectus supplements.
The company’s common stock is listed on the Nasdaq Global Select Market under the symbol GILD. Authorized capital consists of 5,600,000,000 shares of common stock and 5,000,000 shares of preferred stock, with the board empowered to set the rights of any preferred series. Net proceeds from offerings under this shelf may be used for general corporate purposes.
The filing summarizes key terms of potential senior debt securities, including ranking as unsecured obligations, covenants limiting certain liens and sale-leaseback transactions (subject to a 15% consolidated net tangible asset basket), and merger and defeasance provisions under a New York law–governed indenture. It also highlights anti-takeover and exclusive-forum features in Gilead’s charter and bylaws and incorporates by reference its most recent 10-K, 10-Qs and 8-Ks for detailed financial and risk information.
Gilead Sciences reported Q2 2026 total revenues of $7,803 million, up 10% year over year, and first-half revenues of $14,763 million, up 7%. Growth was led by HIV medicines including Biktarvy and Descovy, oncology drug Trodelvy, and liver disease product Livdelzi, partly offset by sharply lower COVID-19 therapy Veklury and weaker cell therapy and HCV sales.
Despite revenue growth, Gilead posted a Q2 net loss of $10,496 million and a first-half net loss of $8,475 million, driven mainly by $11,183 million of acquired in-process R&D expenses for the Arcellx, Tubulis and Ouro Medicines deals and a $1,750 million impairment on a Trodelvy NSCLC asset. Operating cash flow remained strong at $6,117 million for the first half, while total debt, net, rose to $26,246 million. Regulatory highlights included FDA accelerated approval of Hepcludex for hepatitis delta and expanded approvals for Trodelvy, alongside full FDA approval for Tecartus and multiple late-stage oncology and HIV filings.
Gilead Sciences chairman and CEO Daniel O'Day reported selling 15,000 shares of common stock on August 3, 2026, in three transactions described as open market or private at reported prices of $129.6583, $130.8022, and $131.3433 per share. The sales were executed under a Rule 10b5-1 trading plan adopted on February 25, 2026, with execution prices in ranges from $129.17 to $130.16, $130.18 to $131.17, and $131.21 to $131.47 per share.
Gilead Sciences reported strong base-business growth but a large loss for the quarter ended June 30, 2026. Total revenues rose 10% to $7.8 billion, with product sales excluding Veklury up 10% to $7.6 billion, led by 12% HIV growth and higher Trodelvy and Livdelzi sales.
GAAP net loss was $10.5 billion, or $(8.45) per share, versus earnings of $1.56 a year earlier, mainly from $11.2 billion of acquired IPR&D expenses tied to the Arcellx, Tubulis and Ouro Medicines acquisitions and a $1.75 billion IPR&D impairment of Immunomedics assets. Non-GAAP diluted loss per share was $(6.75), down from $2.01.
Cash, cash equivalents and marketable debt securities were $3.2 billion as of June 30, 2026, down from $10.6 billion at year-end after $11.3 billion of acquisition outflows, $2.8 billion of debt repayments and ongoing dividends and buybacks. Management now guides 2026 product sales to $30.1–$30.4 billion, with Veklury around $300 million, and expects a full-year GAAP diluted loss per share of $(3.75) to $(3.40).
An affiliate of GILD filed to sell up to 55,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an indicated value of $7,161,550.00. The shares relate to Restricted Stock Units and Performance Stock Units dated 02/04/2025.
The filing also lists prior Rule 10b5-1 plan sales for Daniel O'Day, including 15,000 shares for $1,894,399.50 on 07/01/2026 and 15,000 shares for $1,971,846.00 on 06/01/2026.
Gilead Sciences, Inc. filed a quarterly institutional holdings report as an institutional investment manager. The report is a Form 13F Holdings Report, indicating that all reportable holdings for this manager are included. The filing covers 5 reportable positions with an aggregate reported value of $1,648,747,919, rounded to the nearest dollar. One additional manager, Gilead Therapeutics A1 Unlimited Co, is listed as an other included manager in the filing.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson carried out an open-market sale of 3,000 shares of common stock on July 15, 2026 at an average price of $129.9256 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, and he continues to hold 168,646 shares directly.
Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences, reported an open-market sale of 3,000 shares of common stock on 2026-07-15 at a reported price of $129.9192 per share, with trade prices ranging from $129.45 to $130.23. This sale was made under a Rule 10b5-1 trading plan adopted on February 20, 2025, and she now directly holds 121,234 Gilead shares.
Johanna Mercier plans to sell 3,000 shares of Gilead common stock through Morgan Stanley Smith Barney LLC on 07/15/2026 on NASDAQ, for an aggregate value of $389,757.60.
The shares come from Performance Shares acquired from the issuer on 02/04/2025. Over the prior three months, Mercier sold 3,000 shares on 06/15/2026 for $371,762.10 and 28,000 shares on 05/15/2026 for $3,676,197.75.